Reading File
Running Command
python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/att…
Running Command
python3 -c " import pdfplumber with pdfplumber.open('/home/daytona/workspace/att…
I now have the full content of the paper. I notice the user hasn't asked a specific question - they just attached the PDF. Let me provide a thorough summary and analysis of the paper.
Here is a detailed summary and analysis of the attached paper:
Paper Overview
Title: Treatment of Small Intestinal Bacterial Overgrowth (SIBO) in Gastrointestinal, Hepatic, Endocrine, Neurological, and Postoperative Diseases: A Comprehensive Narrative Review
Authors: Maslennikov R. et al., Sechenov University, Moscow
Published: Medical Sciences 2026, 14, 300 (June 10, 2026)
Design: Narrative review of 89 studies and 6 meta-analyses identified via PubMed using the search term "small intestinal bacterial overgrowth," with no time limit. Only studies that objectively confirmed SIBO eradication (via negative breath test after therapy) were included.
What Is SIBO?
SIBO is an abnormal increase in bacteria within the small intestine. It is diagnosed primarily via breath tests measuring hydrogen (H₂) and/or methane (CH₄) after a carbohydrate load:
- Hydrogen SIBO - typically presents with diarrhea
- Methane SIBO - associated with slowed motility and constipation
- Mixed SIBO - both gases elevated
Pathophysiologically, excess bacteria produce gas (bloating, pain), osmotically active substances (diarrhea), and can translocate through the portal system to the liver, worsening conditions like cirrhosis. SIBO is found in:
- ~33% of patients with digestive complaints
- ~33% of IBS patients
- ~43% of patients with functional bloating
- ~70% of patients with functional constipation or diarrhea
The Star Drug: Rifaximin
Rifaximin (a non-absorbable antibiotic) is the most-studied SIBO treatment. A recent meta-analysis summarized by the authors showed:
| Rifaximin Dose (mg/day) | SIBO Eradication Rate |
|---|---|
| 600 | 45% |
| 800 | 49% |
| 1200 | 64% |
| 1600 | 80% |
- Overall eradication rate: 63% across all diseases
- Cirrhosis: ~90%
- Functional bowel disease / Parkinson's: ~60%
- Duration (3-28 days) did not significantly affect efficacy
- Critical caveat: When only placebo-controlled RCTs were analyzed (just 4 small RCTs, <30 patients each), rifaximin showed no superiority over placebo. Larger RCTs are urgently needed.
Treatment by Disease Category
Functional Bowel Diseases (IBS, Functional Bloating, Constipation)
Rifaximin (uncontrolled studies):
- IBS: eradication rates vary widely, 16.7%-87.5% depending on dose and duration
- Best results: 1600 mg/day x 7 days (82%), 1200 mg/day x 14 days (~85-87%)
- Adding partially hydrolyzed guar gum (5 g/day) to rifaximin boosted eradication from 62% to 87%
- SIBO recurs in 12.6% at 3 months, 27.5% at 6 months, 43.7% at 9 months
Rifaximin (RCTs with placebo):
- Two small RCTs showed rifaximin was not significantly better than placebo (13-20% vs 14-18%)
Other antibiotics vs. rifaximin:
- Metronidazole 1500 mg x 10 days: 79% (superior to rifaximin's 59% at this dose)
- Ciprofloxacin 1000 mg x 10 days: 54% (similar to rifaximin)
- Neomycin: 20% eradication - superior to placebo in an RCT, but low rate
- Norfloxacin: 100% in a very small RCT (4/4 patients)
Probiotics in IBS:
- Multi-strain probiotic (B. bifidum, B. longum, B. infantis, L. rhamnosus): eliminated SIBO in all 11 patients in one RCT
- Saccharomyces boulardii 250 mg bid: 40% eradication in RCT
- Bacillus subtilis + E. faecium 1500 mg x 4 weeks: 53%, significantly better than placebo
Other interventions:
- Herbal preparations (4 weeks): 46% eradication - similar to rifaximin (34%) in one RCT
- Prucalopride (prokinetic): eliminated SIBO in both constipation-IBS patients in an RCT
- Elemental diet (2 weeks): 58-100% depending on SIBO type (no control group)
- Lubiprostone: 41% in chronic constipation
- Low FODMAP diet: ~50% eradication (comparable to rifaximin ~64% in one RCT)
- Simethicone and curcumin: not effective
Non-Functional Gut Diseases
| Disease | Best Treatment | Eradication Rate | Notes |
|---|---|---|---|
| Crohn's disease | Rifaximin 1200 mg/7d | 100% | Small RCT; 100% recurrence at 1 month |
| Crohn's disease | Metronidazole OR Ciprofloxacin | ~87-100% | Similar efficacy in RCT |
| Diverticular disease | Rifaximin 1200 mg/14d | 83.3% | pRCT, small |
| Lactose intolerance | Rifaximin 1200 mg/14d | 32% | No control group |
| Short bowel syndrome (children) | Multiple antibiotics | Variable | 1 antibiotic sufficient 56% of the time |
| Celiac disease | Rifaximin 800 mg/7d | 100% | Uncontrolled; pRCT showed 33% (= placebo) |
| Chronic intestinal pseudo-obstruction | Rifaximin 1200 mg/28d | 75% | 100% recurrence at 8 weeks |
Cirrhosis
SIBO in cirrhosis is especially significant because it drives bacterial translocation, systemic inflammation, portal hypertension complications, and poor prognosis.
| Treatment | Eradication Rate | Design |
|---|---|---|
| S. boulardii CNCM I-745 500 mg/3 months | 80% | pRCT (strongest evidence) |
| Rifaximin 1200 mg/7d | 94% | Uncontrolled |
| Rifaximin 600 mg/7d | 76% | Uncontrolled |
| VSL#3 probiotic x 3 months | 57.6% | RCT without placebo |
The S. boulardii RCT also showed improvements in hepatic encephalopathy, ascites, albumin, and biomarkers of bacterial translocation and inflammation.
Iatrogenic / Postoperative SIBO
- PPI-induced SIBO: Rifaximin 1200 mg/14d - 68% (H₂) and 53% (CH₄)
- Post-bariatric surgery (RYGB): Probiotics showed no significant effect
- Post-gastrectomy: Rifaximin and metronidazole both largely ineffective (5% and 14% eradication)
- Post-colorectal cancer surgery: Rifaximin 1200 mg/10d - 33%
Other (Non-Digestive) Diseases
| Disease | Treatment | Eradication Rate | Key Effect |
|---|---|---|---|
| Hypothyroidism | Rifaximin 1200 mg/7d | 70% | Reduced abdominal symptoms; no effect on thyroid hormones |
| Hypothyroidism in early pregnancy | Multi-strain probiotic | 71% | Uncontrolled |
| Acromegaly | Rifaximin 1200 mg/10d | 53% | Improved digestive symptoms |
| Systemic sclerosis | Rifaximin (~meta-analysis) | 78% (rifaximin) vs. 45% (other ABX) | Meta-analysis of 9 studies |
| Parkinson's disease | Rifaximin 1200 mg/7d | 78% | Improved motor fluctuations; no effect on levodopa pharmacokinetics |
| Rosacea | Rifaximin 1200 mg/10d | 78-88% | Partial or complete skin symptom regression |
| Cystic fibrosis | Rifaximin 1200 mg/14d | 90% | Improved fat absorption |
| HIV-associated autonomic neuropathy | Pyridostigmine 90 mg/56d | 67% | Prokinetic mechanism |
| Idiopathic halitosis | Bifidobacterium probiotic x 2 months | 80% | Near-universal normalization of oral odor |
| H. pylori infection | Bismuth quadruple eradication | 67-77% | H₂ and CH₄ SIBO eliminated |
Key Conclusions
-
Rifaximin is the most studied drug, with the best safety profile, but its RCT evidence is surprisingly weak - only uncontrolled studies and comparison trials (not placebo-controlled) consistently show benefit. Large placebo-controlled RCTs are needed.
-
Disease-specific treatment selection is important: mechanisms differ (e.g., dysmotility vs. altered gastric acidity vs. anatomical disruption), so responses differ.
-
Probiotics (especially S. boulardii CNCM I-745 and VSL#3) have the strongest RCT evidence in cirrhosis.
-
Post-gastrectomy SIBO is particularly treatment-resistant - both rifaximin and metronidazole show very low eradication rates (<15%).
-
Recurrence is a major problem: 44% of IBS patients who achieve eradication relapse within 9 months; SIBO recurred in all Crohn's patients within 1 month and all pseudo-obstruction patients within 8 weeks.
-
Ongoing RCTs (NCT07451171, NCT07424313, NCT06317441, etc.) are testing low-FODMAP diet, probiotics, herbal extracts, and antibiotic combinations - results are awaited.
-
Limitations of the evidence base: Most studies lack control groups, use varying breath test protocols and cut-offs, and include small patient numbers - making cross-study comparisons difficult.
This is a shared conversation. Sign in to Orris to start your own chat.